Metraipolis › archive › dc_e16d2eade10e

Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority… — Europe PMC PMID:41056494

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41056494
DOI
10.1097/hc9.0000000000000827
License (as archived)
solo-consultazione
Archived
2026-11-09T12:34:27.580Z
SHA-256 of the archived text
7f9f8b7c6dc33d658bd5bb376e280c900b682493df28240cee52e23adeb84f65
Stable URL of this page
https://metraipolis.com/documento/dc_e16d2eade10e

How to cite

Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority… — Europe PMC PMID:41056494 — Europe PMC (en), https://europepmc.org/article/MED/41056494 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e16d2eade10e (Metraipolis archive dc_e16d2eade10e, sha256 7f9f8b7c6dc33d658bd5bb376e280c900b682493df28240cee52e23adeb84f65)
BibTeX
@misc{dce16d2eade10e,
  title = {Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority… — Europe PMC PMID:41056494},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41056494},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e16d2eade10e; sha256 7f9f8b7c6dc33d658bd5bb376e280c900b682493df28240cee52e23adeb84f65},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41056494. Agents can read the archived copy with the MCP tool read_document.